Based on the discovery of the critical regulatory role of the RSK2-IκBα-NF-κB signalling axis44, this study proposes that a leading RSK2 inhibitor holds significant potential for managing pancreatic cancer metastasis (Figures 7 and 8). This evidence concerns the gene RPS6KA3 and familial pancreatic carcinoma.